Sirtuin Signalling and What Resveratrol Actually Does at 75 mg

Resveratrol's trajectory in supplement culture is unusual. It was oversold following early research showing it extended lifespan in yeast and other model organisms. When human trials produced more modest effects, it was dismissed as hype.

Neither position is right. The mechanism is real. The dose, biological context, and species matter — and the early research overstated what rodent data would translate to in humans.

What sirtuins actually do

Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent proteins that regulate cellular responses to energy availability. SIRT1, the primary target of resveratrol, functions as a metabolic sensor: when activated, it promotes mitochondrial biogenesis, supports fatty acid oxidation, reduces inflammatory signalling through deacetylation of NF-κB, and improves insulin sensitivity.

Sirtuin activation is one mechanism through which caloric restriction extends lifespan and improves metabolic function in model organisms — which is why resveratrol attracted such interest as a caloric restriction mimetic. The mechanism is not fantasy. What was overstated was how directly rodent doses and outcomes would translate to human physiology.

The human evidence

Timmers et al. (2011) administered 150 mg/day of resveratrol to obese men for 30 days in a placebo-controlled crossover trial [1]. The study demonstrated caloric restriction-like effects on energy metabolism: reduced metabolic rate adjusted for body composition, reduced intrahepatic lipid, improved insulin sensitivity, reduced plasma glucose and insulin, and improved mitochondrial respiration in skeletal muscle.

The SIRT1 mechanism has been demonstrated in human beta cells and islets, where resveratrol markedly enhanced glucose-stimulated insulin secretion through SIRT1-dependent pathways [2]. Clinical research in people with type 2 diabetes has shown that resveratrol supplementation reduces HOMA-IR — a validated composite measure of insulin resistance — and increases SIRT1 expression in circulating blood cells [3].

Why the dose matters, and why combination matters

The resveratrol literature is complicated by dose variation, formulation differences, and the difficulty of measuring sirtuin activation directly in humans. Studies using 75–150 mg/day have demonstrated effects on vascular function, inflammatory markers, and insulin sensitivity, though effect sizes when resveratrol is studied alone are modest.

This is mechanistically expected. SIRT1 activation is one pathway in a broader metabolic network. When studied alongside AMPK-activating compounds — which target complementary, non-overlapping pathways — additive effects are observed. Berberine activates AMPK. Resveratrol activates SIRT1. Both pathways converge on the same metabolic outcomes: improved insulin sensitivity, fat oxidation, mitochondrial function. Two mechanisms, not one doubled dose.

References

  1. Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-22. PMID: 22055504
  2. Vetterli L, et al. Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E β-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem. 2011;286(8):6049-60. PMID: 21163946
  3. Bhatt JK, et al. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32(7):537-41. PMID: 22901562
Back to blog